CORRECTED-Amgen parathyroid drug succeeds in late-stage trial (Aug 18)

Tue Aug 19, 2014 8:55am EDT

(Corrects headline and paragraph 1 in Aug. 18 story to replace "thyroid" with "parathyroid"))

Aug 18 (Reuters) - Drugmaker Amgen Inc said its experimental drug to reduce parathyroid levels in patients with chronic kidney disease met the main goal in a late-stage trial.

The drug, AMG 416, treats hyperparathyroidism, or excessive secretion of parathyroid hormone, in kidney disease patients.

The results follow the recent announcement of positive data from a placebo-controlled late-stage study of AMG 416, which was similar in design and size. (Reporting By Amrutha Penumudi in Bangalore)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.